Drug Profile
Nimotuzumab - InnoMab
Alternative Names: BIOMAb EGFR; CIMAher; Cimaher; DE-766; h-R3; KI-0501; KI-0502; OSAG101; Taixinsheng; TheraCIM; TheraCIM hR3; Theraloc; VECTHIXLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Center of Molecular Immunology; CIMYM
- Developer Biocon Biopharmaceuticals; Biotech Pharmaceutical; Center of Molecular Immunology; CIMYM; Daiichi Sankyo Inc; Eurofarma; Gilead Sciences; Innogene Kalbiotech; InnoMab; Kuhnil Pharmaceutical Company; Laboratorios Pisa; Oncoscience
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Anaplastic astrocytoma; Brain cancer; Glioblastoma; Glioma; Head and neck cancer; Nasopharyngeal cancer; Oesophageal cancer
- Phase III Cervical cancer; Non-small cell lung cancer; Pancreatic cancer
- Phase II/III Triple negative breast cancer
- Phase II Colorectal cancer
- No development reported Breast cancer; Gastric cancer; Polycystic kidney disease; Prostate cancer
- Discontinued Brain metastases; Squamous cell cancer
Most Recent Events
- 03 Aug 2023 Biotech Pharmaceutical plans a phase III NOTABLE-307 trial in Gastric cancer (Recurrent, Second-line therapy or greater, Metastatic disease, Combination therapy) in September 2023 (IV) (NCT05978050)
- 03 Jun 2022 Efficacy and adverse events data from a phase III trial in Pancreatic cancer were presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
- 03 Jun 2022 Safety and efficacy data from a phase III trial in Nasopharyngeal cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)